March 17, 2008 – A new study analyzed long-term use of the maintenance combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dihydrate), in treating persistent asthma in children 6 to 11 years old. The study examined the safety of SYMBICORT in children for 26 weeks and also included efficacy measures. For children previously treated with inhaled corticosteroid, either alone or in combination, the study showed that long-term treatment with SYMBICORT resulted in significantly greater improvements in lung function and reduced healthcare resource utilization, compared with budesonide dry powder inhaler (DPI) alone. In the study, SYMBICORT also had a safety profile similar to its monocomponent, budesonide, which is an approved asthma medication for children. Results were presented today at the American Academy of Allergy, Asthma & Immunology Annual Meeting held in Philadelphia, March 14-18, 2008... AstraZeneca's Press Release -
Mar 25, 2008
AstraZeneca : Long-Term SYMBICORT® Use In Children With Persistent Asthma
March 17, 2008 – A new study analyzed long-term use of the maintenance combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dihydrate), in treating persistent asthma in children 6 to 11 years old. The study examined the safety of SYMBICORT in children for 26 weeks and also included efficacy measures. For children previously treated with inhaled corticosteroid, either alone or in combination, the study showed that long-term treatment with SYMBICORT resulted in significantly greater improvements in lung function and reduced healthcare resource utilization, compared with budesonide dry powder inhaler (DPI) alone. In the study, SYMBICORT also had a safety profile similar to its monocomponent, budesonide, which is an approved asthma medication for children. Results were presented today at the American Academy of Allergy, Asthma & Immunology Annual Meeting held in Philadelphia, March 14-18, 2008... AstraZeneca's Press Release -
